Immunotherapy and PARP inhibitor combo tested in Hard-to-Treat breast cancer

NCT ID NCT03025035

Completed Disease control Sponsor: Yuan Yuan Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small pilot study tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the PARP inhibitor olaparib (Lynparza) can shrink tumors in people with advanced BRCA-mutated breast cancer. Fourteen participants whose cancer had progressed after prior treatments were enrolled. The main goal was to see how many patients responded to the combination, with tumor assessments every 9 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (Keytruda) and olaparib (Lynparza)
What this could lead to: If this combination works well, it could offer a new treatment option for people with advanced BRCA-mutated breast cancer that has stopped responding to other therapies.
What could go wrong: This is a very small, early-phase pilot study with only 14 participants, so results may not apply to everyone. The cancer is incurable, and the combination may cause significant side effects from both immunotherapy and the PARP inhibitor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.